180 related articles for article (PubMed ID: 28066692)
1. Special Issue on "Cdk5 and Brain Disorders": Prologue.
Kanungo J
Brain Disord Ther; 2012; Suppl 1():. PubMed ID: 28066692
[TBL] [Abstract][Full Text] [Related]
2. Cdk5: multitasking between physiological and pathological conditions.
Lopes JP; Agostinho P
Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899
[TBL] [Abstract][Full Text] [Related]
3. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
4. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology.
Maccioni RB; Otth C; Concha II; Muñoz JP
Eur J Biochem; 2001 Mar; 268(6):1518-27. PubMed ID: 11248668
[TBL] [Abstract][Full Text] [Related]
5. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
6. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
Chen J; Wang ZF
Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
[TBL] [Abstract][Full Text] [Related]
7. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
8. An unusual member of the Cdk family: Cdk5.
Dhariwala FA; Rajadhyaksha MS
Cell Mol Neurobiol; 2008 May; 28(3):351-69. PubMed ID: 18183483
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 5--a neuronal killer?
Guo Q
Sci Aging Knowledge Environ; 2003 Dec; 2003(50):pe36. PubMed ID: 14681576
[TBL] [Abstract][Full Text] [Related]
10. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease.
Allnutt AB; Waters AK; Kesari S; Yenugonda VM
ACS Chem Neurosci; 2020 May; 11(9):1218-1230. PubMed ID: 32286796
[TBL] [Abstract][Full Text] [Related]
11. p39 Is Responsible for Increasing Cdk5 Activity during Postnatal Neuron Differentiation and Governs Neuronal Network Formation and Epileptic Responses.
Li W; Allen ME; Rui Y; Ku L; Liu G; Bankston AN; Zheng JQ; Feng Y
J Neurosci; 2016 Nov; 36(44):11283-11294. PubMed ID: 27807169
[TBL] [Abstract][Full Text] [Related]
12. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
13. Focusing on cyclin-dependent kinases 5: A potential target for neurological disorders.
Tian Z; Feng B; Wang XQ; Tian J
Front Mol Neurosci; 2022; 15():1030639. PubMed ID: 36438186
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinases in brain development and disease.
Su SC; Tsai LH
Annu Rev Cell Dev Biol; 2011; 27():465-91. PubMed ID: 21740229
[TBL] [Abstract][Full Text] [Related]
15. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Hallows JL; Iosif RE; Biasell RD; Vincent I
J Neurosci; 2006 Mar; 26(10):2738-44. PubMed ID: 16525053
[TBL] [Abstract][Full Text] [Related]
16. Physiological and pathological phosphorylation of tau by Cdk5.
Kimura T; Ishiguro K; Hisanaga S
Front Mol Neurosci; 2014; 7():65. PubMed ID: 25076872
[TBL] [Abstract][Full Text] [Related]
17. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective Mechanisms Mediated by CDK5 Inhibition.
Mushtaq G; Greig NH; Anwar F; Al-Abbasi FA; Zamzami MA; Al-Talhi HA; Kamal MA
Curr Pharm Des; 2016; 22(5):527-34. PubMed ID: 26601962
[TBL] [Abstract][Full Text] [Related]
19. Protocols for Characterization of Cdk5 Kinase Activity.
Terse A; Amin N; Hall B; Bhaskar M; B K B; Utreras E; Pareek TK; Pant H; Kulkarni AB
Curr Protoc; 2021 Oct; 1(10):e276. PubMed ID: 34679246
[TBL] [Abstract][Full Text] [Related]
20. The role of CDK5/P25 formation/inhibition in neurodegeneration.
Camins A; Verdaguer E; Folch J; Canudas AM; Pallàs M
Drug News Perspect; 2006 Oct; 19(8):453-60. PubMed ID: 17160145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
